JP2010525073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525073A5 JP2010525073A5 JP2010506460A JP2010506460A JP2010525073A5 JP 2010525073 A5 JP2010525073 A5 JP 2010525073A5 JP 2010506460 A JP2010506460 A JP 2010506460A JP 2010506460 A JP2010506460 A JP 2010506460A JP 2010525073 A5 JP2010525073 A5 JP 2010525073A5
- Authority
- JP
- Japan
- Prior art keywords
- mglur7
- modulator
- use according
- medicament
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 claims 4
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 claims 4
- 206010011878 Deafness Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- YRQCDCNQANSUPB-UHFFFAOYSA-N AMN082 dihydrochloride Chemical group Cl.Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)NCCNC(C=1C=CC=CC=1)C1=CC=CC=C1 YRQCDCNQANSUPB-UHFFFAOYSA-N 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91352007P | 2007-04-23 | 2007-04-23 | |
| US488007P | 2007-11-30 | 2007-11-30 | |
| US2100708P | 2008-01-14 | 2008-01-14 | |
| PCT/US2008/061330 WO2008131439A1 (en) | 2007-04-23 | 2008-04-23 | Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010525073A JP2010525073A (ja) | 2010-07-22 |
| JP2010525073A5 true JP2010525073A5 (enExample) | 2011-06-02 |
Family
ID=39580582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506460A Pending JP2010525073A (ja) | 2007-04-23 | 2008-04-23 | 代謝型グルタミン酸受容体７の調節による老人性難聴の治療及び／又は予防 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100197800A1 (enExample) |
| EP (1) | EP2150244A1 (enExample) |
| JP (1) | JP2010525073A (enExample) |
| WO (1) | WO2008131439A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9132087B2 (en) | 2008-04-21 | 2015-09-15 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| MY161021A (en) | 2008-05-14 | 2017-03-31 | Otonomy Inc | Controlled release corticosteroid and methods for the treatment of otic disorders |
| US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| WO2010048095A2 (en) | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| US9486405B2 (en) | 2013-08-27 | 2016-11-08 | Otonomy, Inc. | Methods for the treatment of pediatric otic disorders |
| WO2015120453A1 (en) | 2014-02-10 | 2015-08-13 | University Of South Florida | Hormone treatment for age-related hearing loss-presbycusis |
| EP3459939A1 (en) * | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
| GB202106871D0 (en) | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202106872D0 (en) | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202216962D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202216963D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202216960D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| KR102847157B1 (ko) | 2023-01-17 | 2025-08-20 | 고려대학교 산학협력단 | 글루타민을 유효성분으로 포함하는 난청 예방 또는 치료용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1255735A2 (en) * | 2000-02-03 | 2002-11-13 | Eli Lilly And Company | Pyridine derivatives as potentiators of glutamate receptors |
| US7507836B2 (en) * | 2003-03-26 | 2009-03-24 | Merck & Co. Inc. | Benzamide modulators of metabotropic glutamate receptors |
| MX2007003922A (es) * | 2004-10-05 | 2007-06-07 | Merz Pharma Gmbh & Co Kgaa | Nuevas propenonas ciclicas y aciclicas para tratar trastornos del sistema nervioso central. |
| KR20070106690A (ko) * | 2004-12-27 | 2007-11-05 | 아스트라제네카 아베 | 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도 |
| RU2008101923A (ru) * | 2005-08-05 | 2009-09-10 | Астразенека Аб (Se) | Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора |
| EP1912940A1 (en) * | 2005-08-12 | 2008-04-23 | AstraZeneca AB | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| GB0517740D0 (en) * | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| TW200819458A (en) * | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
-
2008
- 2008-04-23 JP JP2010506460A patent/JP2010525073A/ja active Pending
- 2008-04-23 EP EP08746706A patent/EP2150244A1/en not_active Ceased
- 2008-04-23 US US12/597,054 patent/US20100197800A1/en not_active Abandoned
- 2008-04-23 WO PCT/US2008/061330 patent/WO2008131439A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525073A5 (enExample) | ||
| JP2010285439A5 (enExample) | ||
| CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
| IL199187A (en) | Indole history, pharmaceuticals including them and their use in the manufacture of medicines | |
| IL234166B (en) | Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine | |
| IL233677A (en) | Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition | |
| JP2007527914A5 (enExample) | ||
| BRPI0822885A2 (pt) | Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral | |
| CL2007001993A1 (es) | Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat | |
| JP2011511805A5 (enExample) | ||
| WO2007135193A3 (fr) | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool | |
| BRPI0810390A2 (pt) | Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero | |
| CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
| JP2007302683A5 (enExample) | ||
| IL206952A (en) | History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines | |
| PL1998762T3 (pl) | Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku | |
| IL211120A (en) | Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection | |
| FR2934156B1 (fr) | Medicament appetissant a administration orale sous forme solide | |
| BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
| IL191310A (en) | A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases | |
| BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| IL201730A (en) | History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs | |
| DK2083638T3 (da) | Smagsfrigivende kerner og deres anvendelse i tyggegummi | |
| CL2007003519A1 (es) | Compuestos derivados de quinolina sustituida; proceso de preparacion; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana. |